Literature DB >> 17291222

Pulmonary alveolar proteinosis: a rare pulmonary toxicity of sirolimus.

Sofia L Pedroso1, La Salete Martins, Sónia Sousa, Abílio Reis, Leonídio Dias, António C Henriques, António M Sarmento, António Cabrita.   

Abstract

The aim of our paper is to describe an unusual pulmonary toxicity of sirolimus (SRL) in a kidney transplant recipient. We present a 34-year-old woman with a second renal transplantation, complicated with steroid-resistant acute rejection and chronic allograft dysfunction. Two years after initiating SRL, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration. She had chronic allograft nephropathy and slight elevation of lactic dehydrogenase levels. After exclusion of common reasons of this condition, a computed tomography (CT) of the thorax and bronchoscopy was performed, revealing ground-glass opacification with polygonal shapes on CT and an opaque appearance with numerous macrophages on bronchoalveolar lavage. The alveolar macrophages stained positive by Periodic acid-Schiff. Diagnosis of pulmonary alveolar proteinosis (PAP) was made and drug-induced toxicity was suspected. SRL was withdrawn with marked improvement in the patients' clinical and radiological status. PAP resolved within 3 months without further therapy. PAP is a very rare complication of SRL therapy with only a few cases described. Withdrawal of SRL with conversion to another immunosuppressant seems to be an appropriate procedure in this condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17291222     DOI: 10.1111/j.1432-2277.2006.00408.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

1.  Pulmonary alveolar proteinosis in a 67-year-old woman with Wegener's granulomatosis.

Authors:  Shiwan K Shah; Nghi B Phan; Geetinder Goyal; Gulshan Sharma
Journal:  J Gen Intern Med       Date:  2010-07-10       Impact factor: 5.128

2.  Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens.

Authors:  Sean Kirby; Anjali Satoskar; Sergey Brodsky; Amy Pope-Harman; David Nunley; Charles Hitchcock; Ronald Pelletier; Patrick Ross; Tibor Nadasdy; Konstantin Shilo
Journal:  Diagn Pathol       Date:  2012-03-14       Impact factor: 2.644

3.  A rare cause of chylous ascites.

Authors:  Yi-Ting Chen; Yung-Ming Chen
Journal:  Clin Kidney J       Date:  2013-12-29

Review 4.  Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature.

Authors:  Patricia Lopez; Sven Kohler; Seema Dimri
Journal:  J Transplant       Date:  2014-12-18

5.  Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis.

Authors:  Kamal Sewaralthahab; Helmut Rennke; Sarah Sewaralthahab; Nicolaos E Madias; Bertrand L Jaber
Journal:  Clin Nephrol Case Stud       Date:  2014-12-15

6.  Sirolimus-induced secondary pulmonary alveolar proteinosis.

Authors:  Stephanie Wang; Elinor Lee; Ryan Lau; Tisha Wang
Journal:  Respir Med Case Rep       Date:  2021-12-15

7.  Lung Transplant Recipient with Pulmonary Alveolar Proteinosis.

Authors:  Sofya Tokman; M Frances Hahn; Hesham Abdelrazek; Tanmay S Panchabhai; Vipul J Patel; Rajat Walia; Ashraf Omar
Journal:  Case Rep Transplant       Date:  2016-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.